🇺🇸 FDA
Pipeline program

Fostamatinib disodium

C-935788-047

Phase 3 small_molecule completed

Quick answer

Fostamatinib disodium for Immune Thrombocytopenic Purpura is a Phase 3 program (small_molecule) at RIGEL PHARMACEUTICALS INC with 3 ClinicalTrials.gov record(s).

Program details

Company
RIGEL PHARMACEUTICALS INC
Indication
Immune Thrombocytopenic Purpura
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials